Postinfectious functional gastrointestinal disorders: A focus on epidemiology and research agendas

Gastroenterology and Hepatology

Volumn 9, Issue 3, 2013, Pages 145-157

  Deising, Adam ^a   Gutierrez, Ramiro L ^b   Porter, Chad K ^b   Riddle, Mark S ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NAVAL MEDICAL RESEARCH CENTER   (United States)

Author keywords

Causation; Dyspepsia; Functional gastrointestinal disorder; Irritable bowel syndrome; Qualitative review

Indexed keywords

ANTIBIOTIC AGENT; DICYCLOVERINE; LAXATIVE; LOPERAMIDE; PLACEBO; PROBIOTIC AGENT; RIFAXIMIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL PAIN; ANTIBIOTIC THERAPY; ARTICLE; BLOATING; CHEMOPROPHYLAXIS; CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DIGESTIVE SYSTEM INFLAMMATION; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE TITRATION; DYSPEPSIA; FOOD POISONING; GASTROENTEROLOGY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL INFECTION; GASTROINTESTINAL MOTILITY DISORDER; HUMAN; INTESTINE MUCOSA PERMEABILITY; IRRITABLE COLON; MICROBIAL COMMUNITY; MIXED INFECTION; MORTALITY; NONHUMAN; NUTRITIONAL INTOLERANCE; POSTINFECTIOUS FUNCTIONAL GASTROINTESTINAL DISORDER; QUALITY ADJUSTED LIFE YEAR; RESEARCH PRIORITY; RISK ASSESSMENT; RISK FACTOR; SALMONELLOSIS; STOMACH PAIN;

EID: 84878430175     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (123)

1. Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther. 2003;17:643-650. (Pubitemid 36418887)
2. Locke GR 3rd, Yawn BP, Wollan PC, Melton LJ 3rd, Lydick E, Talley NJ. Incidence of a clinical diagnosis of the irritable bowel syndrome in a United States population. Aliment Pharmacol Ther. 2004;19:1025-1031. (Pubitemid 38657384)
3. Verdu EF, Riddle MS. Chronic gastrointestinal consequences of acute infectious diarrhea: evolving concepts in epidemiology and pathogenesis. Am J Gastroenterol. 2012;107:981-989.
4. Serghini M, Karoui S, Boubaker J, Filali A. Post-infectious irritable bowel syndrome [in French]. Tunis Med. 2012;90:205-213.
5. Bashashati M, Rezaei N, Andrews CN, et al. Cytokines and irritable bowel syndrome: where do we stand? Cytokine. 2012;57:201-209.
6. Dahlqvist G, Piessevaux H. Irritable bowel syndrome: the role of the intestinal microbiota, pathogenesis and therapeutic targets. Acta Gastroenterol Belg. 2011;74:375-380.
7. Dai C, Jiang M. The incidence and risk factors of post-infectious irritable bowel syndrome: a meta-analysis. Hepatogastroenterology. 2012;59:67-72.
8. Schwille-Kiuntke J, Frick JS, Zanger P, Enck P. Post-infectious irritable bowel syndrome-a review of the literature. Z Gastroenterol. 2011;49:997-1003.
9. Nahas R. Irritable bowel syndrome: common integrative medicine perspectives. Chin J Integr Med. 2011;17:410-413.
10. Pallotti F, Fogacci E, Frisoni C, et al. Post-infectious irritable bowel syndrome [in Italian]. Clin Ter. 2011;162:157-161.
11. Ghoshal UC, Ranjan P. Post-infectious irritable bowel syndrome: the past, the present and the future. J Gastroenterol Hepatol. 2011;26(suppl 3):94-101.
12. Liu J, Hou X. A review of the irritable bowel syndrome investigation on epidemiology, pathogenesis and pathophysiology in China. J Gastroenterol Hepatol. 2011;26(suppl 3):88-93.
13. Qin HY, Wu JC, Tong XD, Sung JJ, Xu HX, Bian ZX. Systematic review of animal models of post-infectious/post-inflammatory irritable bowel syndrome. J Gastroenterol. 2011;46:164-174.
14. Gwee KA. Post-infectious irritable bowel syndrome, an inflammation-immunological model with relevance for other IBS and functional dyspepsia. J Neurogastroenterol Motil. 2010;16:30-34.
15. Ghoshal UC, Park H, Gwee KA. Bugs and irritable bowel syndrome: the good, the bad and the ugly. J Gastroenterol Hepatol. 2010;25:244-251.
16. Thabane M, Marshall JK. Post-infectious irritable bowel syndrome. World J Gastroenterol. 2009;15:3591-3596.
17. Grover M, Herfarth H, Drossman DA. The functional-organic dichotomy: postinfectious irritable bowel syndrome and inflammatory bowel disease-irritable bowel syndrome. Clin Gastroenterol Hepatol. 2009;7:48-53.
18. Dupont AW. Post-infectious irritable bowel syndrome. Curr Gastroenterol Rep. 2007;9:378-384.
19. Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26:535-544. (Pubitemid 47174284)
20. Parascandola M. Causes, risks, and probabilities: probabilistic concepts of causation in chronic disease epidemiology. Prev Med. 2011;53:232-234.
21. Evans AS. Causation and disease: the Henle-Koch postulates revisited. Yale J Biol Med. 1976;49:175-195.
22. Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. Attempt to fulfil Koch's postulates for pyloric Campylobacter. Med J Aust. 1985;142:436-439. (Pubitemid 15233564)
23. Bird A. The epistemological function of Hill's criteria. Prev Med. 2011;53:242-245.
24. Szklo M, Nieto FJ, eds. Epidemiology: Beyond the Basics. 2nd ed. Sudbury, Mass: Jones and Bartlett Publishers; 2007.
25. Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome-a meta-analysis. Am J Gastroenterol. 2006;101:1894-1899.
26. Ruigomez A, Garcia Rodriguez LA, Panes J. Risk of irritable bowel syndrome after an episode of bacterial gastroenteritis in general practice: influence of comorbidities. Clin Gastroenterol Hepatol. 2007;5:465-469. (Pubitemid 46575375)
27. Zanini B, Ricci C, Bandera F, et al. Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak. Am J Gastroenterol. 2012;107:891-899.
28. Ji S, Park H, Lee D, Song YK, Choi JP, Lee SI. Post-infectious irritable bowel syndrome in patients with Shigella infection. J Gastroenterol Hepatol. 2005;20:381-386. (Pubitemid 40469337)
29. Porter CK, Gormley R, Tribble DR, Cash BD, Riddle MS. The incidence and gastrointestinal infectious risk of functional gastrointestinal disorders in a healthy US adult population. Am J Gastroenterol. 2010;106:130-138.
30. Tuteja AK, Talley NJ, Gelman SS, et al. Development of functional diarrhea, constipation, irritable bowel syndrome, and dyspepsia during and after traveling outside the USA. Dig Dis Sci. 2008;53:271-276. (Pubitemid 350265680)
31. Marshall JK, Thabane M, Borgaonkar MR, James C. Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen. Clin Gastroenterol Hepatol. 2007;5:457-460. (Pubitemid 46575359)
32. Mearin F, Perez-Oliveras M, Perello A, et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology. 2005;129:98-104. (Pubitemid 41002046)
33. Parry SD, Stansfield R, Jelley D, et al. Is irritable bowel syndrome more common in patients presenting with bacterial gastroenteritis? A community-based, case-control study. Am J Gastroenterol. 2003;98:327-331. (Pubitemid 36232381)
34. Villani AC, Lemire M, Thabane M, et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology. 2010;138:1502-1513.
35. Porter CK, Tribble DR, Aliaga PA, Halvorson HA, Riddle MS. Infectious gastroenteritis and risk of developing inflammatory bowel disease. Gastroenterology. 2008;135:781-786.
36. Swan C, Duroudier NP, Campbell E, et al. Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFalpha. Gut. 2012 Jun 8. Epub ahead of print.
37. Porter CK, Cash BD, Pimentel M, Akinseye A, Riddle MS. Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome. BMC Gastroenterol. 2012;12:55.
38. Marshall JK, Thabane M, Garg AX, Clark WF, Salvadori M, Collins SM. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology. 2006;131:445-450; quiz 660. (Pubitemid 44142459)
39. Thabane M, Simunovic M, Akhtar-Danesh N, Marshall JK. Development and validation of a risk score for post-infectious irritable bowel syndrome. Am J Gastroenterol. 2009;104:2267-2274.
40. Mearin F. Postinfectious functional gastrointestinal disorders. J Clin Gastroenterol. 2011;45(suppl):S102-S105.
41. Dupont HL. Gastrointestinal infections and the development of irritable bowel syndrome. Curr Opin Infect Dis. 2011;24:503-508.
42. Sethi S, Garey KW, Arora V, et al. Increased rate of irritable bowel syndrome and functional gastrointestinal disorders after Clostridium difficile infection. J Hosp Infect. 2011;77:172-173.
43. Thabane M, Simunovic M, Akhtar-Danesh N, Garg AX, Clark WF, Marshall JK. Clustering and stability of functional lower gastrointestinal symptom after enteric infection. Neurogastroenterol Motil. 2012;24:546-552, e252.
44. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ. 1997;314:779-782. (Pubitemid 27117047)
45. Morabia A. Until the lab takes it away from epidemiology. Prev Med. 2011;53:217-220.
46. Collins SM, Denou E, Verdu EF, Bercik P. The putative role of the intestinal microbiota in the irritable bowel syndrome. Dig Liver Dis. 2009;41:850-853.
47. Rutella S, Locatelli F. Intestinal dendritic cells in the pathogenesis of inflammatory bowel disease. World J Gastroenterol. 2011;17:3761-3775.
48. Wells JM, Rossi O, Meijerink M, van Baarlen P. Epithelial crosstalk at the microbiota-mucosal interface. Proc Natl Acad Sci U S A. 2011;108(suppl 1):4607-4614.
49. Fukudo S, Kanazawa M. Gene, environment, and brain-gut interactions in irritable bowel syndrome. J Gastroenterol Hepatol. 2011;26(suppl 3):110-115.
50. Mearin F, Perello A, Balboa A, et al. Pathogenic mechanisms of postinfectious functional gastrointestinal disorders: results 3 years after gastroenteritis. Scand J Gastroenterol. 2009;44:1173-1185.
51. Jung IS, Kim HS, Park H, Lee SL. The clinical course of post-infectious irritable bowel syndrome: a five-year follow-up study. J Clin Gastroenterol. 2009;43:534-540.
52. Landzberg BR, Connor BA. Persistent diarrhea in the returning traveler: think beyond persistent infection. Scand J Gastroenterol. 2005;40:112-124.
53. Misra S, Sabui TK, Basu S, Pal N. A prospective study of rotavirus diarrhea in children under 1 year of age. Clin Pediatr (Phila). 2007;46:683-688. (Pubitemid 47366761)
54. Green P, Jabri B. Coeliac disease. Lancet. 2003;362:383-391. (Pubitemid 36945070)
55. Mendelson RM, Wright SG, Tomkins AM. Coeliac disease presenting as malabsorption from the tropics. Gut. 1978;19:992.
56. Riddle MS, Murray JA. The incidence and risk of celiac disease in a healthy US adult population. Am J Gastroenterol. 2012;107:1248-1255.
57. Green PH, Cellier C. Celiac disease. N Engl J Med. 2007;357:1731-1743.
58. Troncone R, Bhatnagar S, Butzner D, Cameron D, Hill I, Hoffenberg E. European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Coeliac disease and other immunologically mediated disorders of the gastrointestinal tract: Working Group report of the second World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2004;39:S601-S610.
59. van Sommeren S, Visschedijk MC, Festen EA, et al. HNF4α and CDH1 are associated with ulcerative colitis in a Dutch cohort. Inflamm Bowel Dis. 2011;17:1714-1718.
60. Salonen A, de Vos WM, Palva A. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology. 2010;156:3205-3215.
61. Tosh PK, McDonald LC. Infection control in the multidrug-resistant era: tending the human microbiome. Clin Infect Dis. 2012;54:707-713.
62. Rajilic-Stojanovic M, Biagi E, Heilig HG, et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011;141:1792-1801.
63. Talley NJ, Fodor AA. Bugs, stool, and the irritable bowel syndrome: too much is as bad as too little? Gastroenterology. 2011;141:1555-1559.
64. Carroll IM, Ringel-Kulka T, Keku TO, et al. Molecular analysis of the luminal-and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2011;301:G799-G807.
65. Soyturk M, Akpinar H, Gurler O, et al. Irritable bowel syndrome in persons who acquired trichinellosis. Am J Gastroenterol. 2007;102:1064-1069. (Pubitemid 46698220)
66. Hanevik K, Dizdar V, Langeland N, Hausken T. Development of functional gastrointestinal disorders after Giardia lamblia infection. BMC Gastroenterol. 2009;9:27.
67. Uzoigwe JC, Khaitsa ML, Gibbs PS. Epidemiological evidence for Mycobacterium avium subspecies paratuberculosis as a cause of Crohn's disease. Epidemiol Infect. 2007;135:1057-1068. (Pubitemid 47487591)
68. Keating C, Beyak M, Foley S, et al. Afferent hypersensitivity in a mouse model of post-inflammatory gut dysfunction: role of altered serotonin metabolism. J Physiol. 2008;586:4517-4530.
69. Lee KJ, Kim YB, Kim JH, Kwon HC, Kim DK, Cho SW. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol. 2008;23:1689-1694.
70. Barbara G, Cremon C, Carini G, et al. The immune system in irritable bowel syndrome. J Neurogastroenterol Motil. 2011;17:349-359.
71. Valentini L, Eggers J, Ockenga J, et al. Association between intestinal tight junction permeability and whole-body electrical resistance in healthy individuals: a hypothesis. Nutrition. 2009;25:706-714.
72. Camilleri M, Madsen K, Spiller R, Greenwood-Van Meerveld B, Verne GN. Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil. 2012;24:503-512.
73. Barbara G, Vallance BA, Collins SM. Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice. Gastroenterology. 1997;113:1224-1232. (Pubitemid 27418976)
74. Bercik P, Wang L, Verdu EF, et al. Visceral hyperalgesia and intestinal dysmotility in a mouse model of postinfective gut dysfunction. Gastroenterology. 2004;127:179-187. (Pubitemid 38962286)
75. Fernandez-Blanco JA, Barbosa S, Sanchez de Medina F, Martinez V, Vergara P. Persistent epithelial barrier alterations in a rat model of postinfectious gut dysfunction. Neurogastroenterol Motil. 2011;23:e523-e533.
76. Saito YA. The role of genetics in IBS. Gastroenterol Clin North Am. 2011;40:45-67.
77. Camilleri M, Katzka DA. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;302:G1075-G1084.
78. Camilleri M, Carlson P, Zinsmeister AR, et al. Mitochondrial DNA and gastrointestinal motor and sensory functions in health and functional gastrointestinal disorders. Am J Physiol Gastrointest Liver Physiol. 2009;296:G510-G516.
79. Jee SR, Morales W, Low K, et al. ICC density predicts bacterial overgrowth in a rat model of post-infectious IBS. World J Gastroenterol. 2010;16:3680-3686.
80. US Preventive Services Task Force. Guide to Clinical Preventive Services: Report of the US Preventive Services Task Force. Washington, DC: DIANE Publishing; 1989.
81. Howick J, Chalmers I, Glasziou P, et al. Explanation of the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of Evidence (Background Document). Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index. aspx?o=5653. Accessed February 4, 2013.
82. Durrheim DN, Reingold A. Modifying the GRADE framework could benefit public health. J Epidemiol Community Health. 2010;64:387.
83. Schunemann H, Hill S, Guyatt G, Akl EA, Ahmed F. The GRADE approach and Bradford Hill's criteria for causation. J Epidemiol Community Health. 2011;65:392-395.
84. Robberstad B. QALYs vs DALYs vs LYs gained: what are the differences, and what difference do they make for health care priority setting? Norsk Epidemiologi. 2005;15:183-191. (Pubitemid 43197903)
85. Janssen MF, Birnie E, Bonsel G. Feasibility and reliability of the annual profile method for deriving QALYs for short-term health conditions. Med Decis Making. 2008;28:500-510. (Pubitemid 351989992)
86. Haagsma JA, Siersema PD, De Wit NJ, Havelaar AH. Disease burden of post-infectious irritable bowel syndrome in The Netherlands. Epidemiol Infect. 2010;138:1650-1656.
87. Scallan E, Hoekstra RM, Angulo FJ, et al. Foodborne illness acquired in the United States-major pathogens. Emerg Infect Dis. 2011;17:7-15.
88. Patel RP, Petitta A, Fogel R, Peterson E, Zarowitz BJ. The economic impact of irritable bowel syndrome in a managed care setting. J Clin Gastroenterol. 2002;35:14-20. (Pubitemid 34663344)
89. Levy RL, Von Korff M, Whitehead WE, et al. Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol. 2001;96:3122-3129. (Pubitemid 33095351)
90. Tang YR, Yang WW, Wang YL, Lin L. Sex differences in the symptoms and psychological factors that influence quality of life in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2012;24:702-707.
91. Scharff RL. Health-related costs from foodborne illness in the United States: Food Safety Project. http://www.pewhealth.org/uploadedFiles/PHG/Content- Level-Pages/Reports/PSP-Scharff%20v9.pdf. Accessed February 4, 2013.
92. Shah ED, Riddle MS, Chang C, Pimentel M. Estimating the contribution of acute gastroenteritis to the overall prevalence of irritable bowel syndrome. J Neurogastroenterol Motil. 2012;18:200-204.
93. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. Gastroenterology. 2009;136:376-386.
94. Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut. 2010;59:605-611.
95. Reidpath DD, Allotey PA, Kouame A, Cummins RA. Measuring health in a vacuum: examining the disability weight of the DALY. Health Policy Plan. 2003;18:351-356. (Pubitemid 37498534)
96. Anand S, Hanson K. Disability-adjusted life years: a critical review. J Health Econ. 1997;16:685-702. (Pubitemid 28046571)
97. DuPont HL, Galler G, Garcia-Torres F, Dupont AW, Greisinger A, Jiang ZD. Travel and travelers' diarrhea in patients with irritable bowel syndrome. Am J Trop Med Hyg. 2010;82:301-305.
98. Talley NJ. Overlapping abdominal symptoms: why do GERD and IBS often coexist? Drugs Today (Barc). 2006;42(suppl B):3-8. (Pubitemid 46422078)
99. Talley NJ. A unifying hypothesis for the functional gastrointestinal disorders: really multiple diseases or one irritable gut? Rev Gastroenterol Disord. 2006;6:72-78. (Pubitemid 43826898)
100. Nakajima S, Takahashi K, Sato J, et al. Spectra of functional gastrointestinal disorders diagnosed by Rome III integrative questionnaire in a Japanese outpatient office and the impact of overlapping. J Gastroenterol Hepatol. 2010;25(suppl 1):S138-S143.
101. Spence MJ, Moss-Morris R. The cognitive behavioural model of irritable bowel syndrome: a prospective investigation of patients with gastroenteritis. Gut. 2007;56:1066-1071. (Pubitemid 47123235)
102. Almela P, Benages A, Peiro S, et al. A risk score system for identification of patients with upper-GI bleeding suitable for outpatient management. Gastrointest Endosc. 2004;59:772-781. (Pubitemid 38885677)
103. Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol. 2005;42(suppl):S100-S107. (Pubitemid 40364609)
104. Papachristou GI, Muddana V, Yadav D, et al. Comparison of BISAP, Ranson's, APACHE-II, and CTSI scores in predicting organ failure, complications, and mortality in acute pancreatitis. Am J Gastroenterol. 2010;105:435-441; quiz 442.
105. McKeown ES, Parry SD, Stansfield R, Barton JR, Welfare MR. Postinfectious irritable bowel syndrome may occur after non-gastrointestinal and intestinal infection. Neurogastroenterol Motil. 2006;18:839-843.
106. Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol. 2003;98:1578-1583. (Pubitemid 36875351)
107. Dorn SD, Morris CB, Hu Y, et al. Irritable bowel syndrome subtypes defined by Rome II and Rome III criteria are similar. J Clin Gastroenterol. 2009;43:214-220.
108. Halder SL, Talley NJ. Functional dyspepsia: a new Rome III paradigm. Curr Treat Options Gastroenterol. 2007;10:259-272. (Pubitemid 47193510)
109. Wang A, Liao X, Xiong L, et al. The clinical overlap between functional dyspepsia and irritable bowel syndrome based on Rome III criteria. BMC Gastroenterol. 2008;8:43.
110. Kang SH, Choi SW, Lee SJ, et al. The effects of lifestyle modification on symptoms and quality of life in patients with irritable bowel syndrome: a prospective observational study. Gut Liver. 2011;5:472-477.
111. Barrett JS, Gibson PR. Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals? Ther Adv Gastroenterol. 2012;5:261-268.
112. Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011:CD003460.
113. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med. 2000;133:136-137.
114. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol. 2009;15:1548-1553.
115. Dunlop SP, Jenkins D, Neal KR, et al. Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther. 2003;18:77-84. (Pubitemid 36897983)
116. Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil. 2003;15:79-86. (Pubitemid 36313138)
117. Pimentel M, Morales W, Jee SR, et al. Antibiotic prophylaxis prevents the development of a post-infectious phenotype in a new rat model of post-infectious IBS. Dig Dis Sci. 2011;56:1962-1966.
118. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009;104:1033-1049; quiz 1050.
119. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22-32.
120. Alajbegovic S, Sanders JW, Atherly DE, Riddle MS. Effectiveness of rifaximin and fluoroquinolones in preventing travelers' diarrhea (TD): a systematic review and meta-analysis. Syst Rev. 2012;1:39.
121. Hurst AF. Medical Diseases of the War. London, United Kingdom: E. Arnold; 1917.
122. Gwee KA, Graham JC, McKendrick MW, et al. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet. 1996;347:150-153. (Pubitemid 26025154)
123. Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut. 2002;51:410-413.